Ya Chao Zhao

Shanghai Bioveda Investment Management Consulting Co. Ltd. (BioVeda China) is an independent Chinese venture capital firm which was established by Dr. Zhi Yang when BioVeda Capital spun off their China Fund. Headquartered in Shanghai, BioVeda China is the first international life science venture capital firm in China and manages the BioVeda China Fund, backed by blue chip international institutional and corporate investors. The firm's Scientific Advisory Board, comprised of international experts from China and the West, supports BioVeda China by acting as a business and scientific bridge between companies in China and the West, linking finance and technology between the two markets.

Part of Shanghai Bioveda Investment Management Consulting Co. Ltd., BVCF Investment Consulting (Shanghai) Ltd. is a healthcare investment company based in Shanghai, China. BVCF actively assists business owners and entrepreneurs to build their companies into world-class businesses. The Chinese company has raised five funds and invests in growth-stage healthcare companies from around the world, with a particular focus on innovative solutions that address unmet health needs. The private company was founded by Zhi Yang and Ya Chao Zhao has been the CEO of the company since 2007.

Shanghai Drug Farm Biological Technology Co., Ltd. is a Chinese private biotechnology company that focuses on developing innovative treatments for hepatitis B, heart and kidney diseases, and ROSAH syndrome. The company utilizes breakthrough technologies in genetics and AI to discover new treatments through its unique IDinVivo platform. This platform allows the direct assessment of gene targets in living animals with intact immune systems, which has led to the identification of novel innate immunity pathways and targets. Drug Farm is now advancing multiple first-in-class drug candidates into clinical development.

CARsgen Therapeutics Co., Ltd. develops an immunotherapy cancer treatment. It develops a novel cell-based immunotherapy using T-cells carrying chimeric antigen receptor technology for cancer treatment. The company was founded by ZongHai Li in 2014 and is headquartered in Shanghai, China.